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medication; “appropriate therapy”) and CHBNAi (CUs not
using any anti-inﬂammatory medication). Univariate analyses for
continuous variables was performed using Mann-Whitney U test;
and multivariate logistic regression was performed to predict the
probability of being on appropriate therapy. RESULTS: A total
of 1127 chronic users were identiﬁed (474 before and 653 after
the introduction of the guidelines). A higher proportion of
CHBYAi patients were found after the introduction of the guide-
lines (7%, Chi-square test, p-value = 0.041). However, both
before and after the introduction of the guidelines the CHBNAi
had signiﬁcantly fewer asthma-related total (physician, ER and
hospital) visits and costs (all p-value = 0.000). Multivariate logis-
tic regression results indicated that total asthma-related visits
was signiﬁcantly associated with the odds of being on appropri-
ate therapy. Before the guidelines, for every asthma related visit
the odds of being on appropriate guidelines was found to be
1.544 (95% CI: 1.327–1.797); for every asthma related visit the
odds of being on appropriate therapy was found to be 1.937
(95%CI: 1.624–2.309). CONCLUSION: We would have
expected a higher health care utilization (visits & cost) for the
CHBNAi group but we could not conclude this.
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COSTS FOR ASTHMA-RELATED MEDICAL SERVICES 
AND PRESCRIPTION MEDICATIONS IN A STATE 
MEDICAID PROGRAM
D’Souza A, Smith MJ
West Virginia University, Morgantown, WV, USA
Previous studies have shown that costs for asthma care tend to
be higher among recipients of Medicaid compared to patients
covered by private insurance. OBJECTIVE: Report the costs for
asthma-related health care in a state Medicaid Program.
METHODS: Medicaid medical services claims with a primary
ICD-9 diagnosis code for asthma dated 2002 were extracted.
Matching claims for asthma-related prescription medications
also were collected. Costs for outpatient visits, emergency
department (ED) visits, and prescriptions were based on dollars
reimbursed by Medicaid. Costs for hospitalizations were esti-
mated based on average DRG reimbursements. RESULTS: There
were 16,573 recipients with claims for asthma. Among demo-
graphic groups, a majority of recipients were younger than 15
years (44%), female (58%), and white (93%). Medicaid paid
roughly $12.9 million for asthma-related medical services and
prescriptions, or an average of $779 per recipient with asthma.
A majority of the dollars were paid for services and prescriptions
utilized by adults between 21 and 64 years of age (49%), females
(61%), and caucasians (93%). Hospitalization costs amounted
to $3.5 million (27% of the total) at an average cost of nearly
$4000 per admission. ED costs equaled over $619,000 (5% of
the total) at an average cost of $169 per visit. Outpatient costs
were nearly $2.4 million (19% of the total) at an average cost
of $83 per visit. Prescription costs totaled $6.2 million (48% of
the total) for an average cost of $51 per prescription. A major-
ity of the dollars paid for prescriptions were for leukotriene mod-
iﬁers (33%), short-acting beta-agonists (23%), and inhaled
corticosteroids (21%). CONCLUSIONS: Asthma is responsible
for a substantial consumption of economic resources of the Med-
icaid Program. Roughly half of the dollars Medicaid spends for
asthma care is for medical services and half for prescription
drugs. Hospitalizations account for a majority of medical ser-
vices costs.
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THE EFFECT OF MEDICAID COVERAGE DECISIONS ON NON-
SEDATING ANTIHISTAMINE UTILIZATION AND SPENDING
FOLLOWING OVER-THE-COUNTER AVAILABILITY 
OF LORATADINE
Hansen RA,Trygstad TK
University of North Carolina—Chapel Hill, Chapel Hill, NC, USA
OBJECTIVES: This study evaluates the effect of over-the-
counter (OTC) availability of loratadine on utilization and
spending in a state Medicaid population without OTC coverage.
Using a subset of nearly 100,000 enrollees before and after
loratadine OTC availability, the speciﬁc objectives of this study
were to: 1) evaluate product switching behavior; 2) describe non-
sedating antihistamine utilization patterns; and 3) describe non-
sedating antihistamine expenditures and their response to OTC
availability. METHODS: The study was conducted retrospec-
tively using paid pharmacy claims for a subset of Medicaid 
beneﬁciaries. Non-sedating antihistamine use was evaluated for
two 12 month intervals encompassing July 1, 2001 through June
30, 2003. Within each interval, the rate of product switching
between the ﬁrst 5 months and last 5 months was evaluated.
Trends in utilization and spending were tracked for the entire
24-month period. RESULTS: Beneﬁciaries using loratadine in the
OTC availability interval were 2.4 (95% CI; 2.08–2.41) times
more likely to switch to a different non-sedating antihistamine
and 1.09 (95% CI: 1.08–1.12) times more likely to not have a
non-sedating antihistamine claim than beneﬁciaries in the non-
OTC availability interval. The largest gain in market share was
observed for cetirizine, although desloratadine accounted for the
largest switch rate from loratadine. During the ﬁrst 12 months
of the study, non-sedating antihistamine expenditures increased
by nearly $28,000 per month. Despite availability of a less costly
alternative, expenditures increased by $13,000 per month during
the last 12 months. CONCLUSIONS: Although utilization and
spending tapered slightly after the introduction of loratadine
OTC, the majority of beneﬁciaries using loratadine switched to
a covered alternative once the OTC product was on the market.
Given the potential cost-savings associated with OTC loratadine
(compared to the prescription only competitors) and the high
likelihood of switching, it appears that state Medicaid programs
should consider coverage of both prescription and OTC 
products.
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OBJECTIVE: To identify patient behaviors that affect adherence
regarding asthma and its management using Q-methodology.
New insight into patient attitudes may facilitate further devel-
opment of interventions, which remove barriers affecting adher-
ence in asthma. While many theoretical frames have been
proposed, this is the ﬁrst application of Q-methodology to this
problem. METHODS: A literature search, and interviews with
clinicians and patients were used to create a concourse of reasons
for non-adherence in asthma. The raw set of ideas in the con-
course were deﬁned, clariﬁed and combined into more mean-
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ingful statements to form a Q-set. Statements in the Q-set were
pilot tested for understanding and redundancy in a small group
of asthma patients. Thirty-eight statements were included in the
ﬁnal Q-set. Forty-ﬁve study respondents rank ordered the set 
of statements by a structured command called the condition of
instruction. The resultant pattern of distribution of statements
formed a Q-sort. After the Q-sorts were formed, by-person
factor analysis was conducted to ﬁnd clusters of Q-sorts with
shared similarities or common attitudes. RESULTS: Five subjec-
tive attitudes were identiﬁed that may inﬂuence adherence with
asthma regimens. 1) respondents did not want to be dependent
on their medication and would rather take medication once a
day; 2) respondents did not like others knowing they took med-
ication and thought they were taking too much medication; 3)
respondents did not feel they were sick and thought they did not
need medication if they removed triggers from their home; 4)
respondents did not believe their medications worked and had
other priorities than to worry about their asthma; and 5) respon-
dents did not want to be dependent on their medication and
believed they were taking too much medication. CONCLU-
SION: Interventions to improve adherence can be targeted to the
characteristics of patients deﬁned in the factors from the 
Q-analysis.
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OBJECTIVE: To examine the relationship between patient,
disease, and treatment variables and self-reported compliance
with asthma controller medications. METHODS: This was a 
secondary analysis from a cross-sectional study of adults with
asthma enrolled in a managed-care organization (MCO). Data
were obtained from a mailed questionnaire and the MCO’s
patient/claims databases. Compliance was reported using the 
4-item questionnaire developed by Brooks, et al. and scored as
a mean of the responses, with 5 meaning highest compliance.
Independent variables included age, gender, race, education,
number of comorbidities, years with asthma, health-belief ques-
tions, social support, income, number of MDI instructors,
inhaler technique, perceived physician access, patient-perceived
severity, guideline-derived severity, and three health-related
quality of life scores, the Asthma Quality of Life Questionnaire
(AQLQ) summary and the physical (PCS) and mental (MCS)
component summaries of the SF-36. Multivariate regression
analysis was used to determine the independent variables with
the strongest relationship to self-reported compliance. Stepwise
backward-elimination was used, with the ﬁnal model consisting
of variables with a p < 0.05. RESULTS: The 573 respondents
were primarily Caucasian (89.5%) and female (71.0%), with an
average age of 40.5 ± 12.4 years (mean ± SD) and average
asthma duration of 18.3 ± 14.2 years. The mean compliance
scale score was 3.7 ± 1.1, with 84.6% indicating some level of
noncompliance (score < 5). The ﬁnal model had an adjusted R2
of 0.26 and included 6 independent variables. Better adherence
was associated with longer duration of asthma, more MDI
instructors, lack of depression, stronger beliefs in the beneﬁts of
treatment and trigger avoidance, and greater perceived severity
of asthma. CONCLUSIONS: A complex set of beliefs, percep-
tions, and experiences constitute the variables associated with
compliant medication-taking behavior. Future longitudinal
studies should include these variables to determine the predictive
strength of the model.
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OBJECTIVE: Prior studies have investigated the association
between generic health related quality of life (HRQOL) and
adherence. The objective of this study is to assess the association
between medication adherence HRQOL using disease speciﬁc in
addition to generic instruments. METHODS: As part of a larger
study a convenience sample of adult ambulatory asthma patients
were recruited from community pharmacies in GA, USA. Adult
asthma patients identiﬁed to participate in the study were asked
to complete a self-administered HRQOL survey. Patients were
asked to complete generic (Short Form—SF-12, Health Utilities
Index3—HUI3, EuroQol Index—EQ5D, EuroQoL visual 
analogue scale—EQVAS) and disease speciﬁc (Juniper’s 
mini-Asthma Quality of Life Questionnaire—AQLQ) HRQOL
metrics. Adherence was measured using Morisky’s instrument.
Asthma control was assessed using Juniper’s Asthma Control
Questionnaire (ACQ, objective measure) in addition to a self
assessment (5-point Likert Scale, subjective measure). SF-12 was
assessed using mental and physical summary scores (MCS and
PCS, respectively). RESULTS: Data were available on a conve-
nience sample of 36 patients (25 female: 11 male) with an
average age of 44.8 years. Spearman correlation between ACQ
and self assessed asthma control was high (r = -0.825, p <
0.001). Excluding PCS, spearman correlations between asthma
control metrics (subjective and objective) and HRQOL measures
were moderate to high in the predicted direction (r = 0.52 to
0.822). However, correlations between adherence and HRQOL
measures were not signiﬁcant. Quick relief beta-agonist use was
also highly correlated with ACQ (r = 0.67, p < 0.01) and mod-
erately with HRQOL instruments in the predicted direction.
CONCLUSION: Overall, our study ﬁndings show no associa-
tion between adherence and HRQOL, supporting the results by
Cote and colleagues (2003) that factors other than medication
compliance are important in explaining HRQOL. Asthma
control is a potentially important variable in predicting HRQOL
in asthma patients.
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OBJECTIVE: The objective of this study is to assess the associ-
ation between health state utilities, HRQOL and willingness to
pay. METHODS: As part of a larger study a convenience sample
of adult ambulatory asthma patients were recruited from com-
munity pharmacies in the state of Georgia, USA. Adult asthma
patients identiﬁed to participate in the study were asked to com-
plete a self-administered HRQOL survey. Patients were asked to
complete generic (Short Form—SF-12, Health Utilities Index3—
HUI3, EuroQol Index—EQ5D, EuroQoL visual analogue
scale—EQVAS) and disease speciﬁc (Juniper’s mini-Asthma
Quality of Life Questionnaire—AQLQ) HRQOL instruments.
SF-12 was assessed using mental and physical summary scores
(MCS and PCS, respectively). Willingness to pay (WTP) was
assessed using the payment card approach for two scenarios: a
hypothetical asthma cure and a treatment. RESULTS: Majority
